221 related articles for article (PubMed ID: 15691665)
1. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat.
Luurtsema G; Molthoff CF; Schuit RC; Windhorst AD; Lammertsma AA; Franssen EJ
Nucl Med Biol; 2005 Jan; 32(1):87-93. PubMed ID: 15691665
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET.
Lubberink M; Luurtsema G; van Berckel BN; Boellaard R; Toornvliet R; Windhorst AD; Franssen EJ; Lammertsma AA
J Cereb Blood Flow Metab; 2007 Feb; 27(2):424-33. PubMed ID: 16757979
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil.
Takano A; Kusuhara H; Suhara T; Ieiri I; Morimoto T; Lee YJ; Maeda J; Ikoma Y; Ito H; Suzuki K; Sugiyama Y
J Nucl Med; 2006 Sep; 47(9):1427-33. PubMed ID: 16954549
[TBL] [Abstract][Full Text] [Related]
4. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography.
Sasongko L; Link JM; Muzi M; Mankoff DA; Yang X; Collier AC; Shoner SC; Unadkat JD
Clin Pharmacol Ther; 2005 Jun; 77(6):503-14. PubMed ID: 15961982
[TBL] [Abstract][Full Text] [Related]
5. (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus.
Syvänen S; Luurtsema G; Molthoff CF; Windhorst AD; Huisman MC; Lammertsma AA; Voskuyl RA; de Lange EC
BMC Med Imaging; 2011 Jan; 11():1. PubMed ID: 21199574
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function.
Ikoma Y; Takano A; Ito H; Kusuhara H; Sugiyama Y; Arakawa R; Fukumura T; Nakao R; Suzuki K; Suhara T
J Nucl Med; 2006 Sep; 47(9):1531-7. PubMed ID: 16954563
[TBL] [Abstract][Full Text] [Related]
7. (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation.
Luurtsema G; Molthoff CF; Windhorst AD; Smit JW; Keizer H; Boellaard R; Lammertsma AA; Franssen EJ
Nucl Med Biol; 2003 Oct; 30(7):747-51. PubMed ID: 14499333
[TBL] [Abstract][Full Text] [Related]
8. Developmental changes in P-glycoprotein function in the blood-brain barrier of nonhuman primates: PET study with R-11C-verapamil and 11C-oseltamivir.
Takashima T; Yokoyama C; Mizuma H; Yamanaka H; Wada Y; Onoe K; Nagata H; Tazawa S; Doi H; Takahashi K; Morita M; Kanai M; Shibasaki M; Kusuhara H; Sugiyama Y; Onoe H; Watanabe Y
J Nucl Med; 2011 Jun; 52(6):950-7. PubMed ID: 21571790
[TBL] [Abstract][Full Text] [Related]
9. Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier.
de Klerk OL; Willemsen AT; Roosink M; Bartels AL; Hendrikse NH; Bosker FJ; den Boer JA
Int J Neuropsychopharmacol; 2009 Aug; 12(7):895-904. PubMed ID: 19224656
[TBL] [Abstract][Full Text] [Related]
10. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography.
Toornvliet R; van Berckel BN; Luurtsema G; Lubberink M; Geldof AA; Bosch TM; Oerlemans R; Lammertsma AA; Franssen EJ
Clin Pharmacol Ther; 2006 Jun; 79(6):540-8. PubMed ID: 16765142
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil.
Lee YJ; Maeda J; Kusuhara H; Okauchi T; Inaji M; Nagai Y; Obayashi S; Nakao R; Suzuki K; Sugiyama Y; Suhara T
J Pharmacol Exp Ther; 2006 Feb; 316(2):647-53. PubMed ID: 16293715
[TBL] [Abstract][Full Text] [Related]
12. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
[TBL] [Abstract][Full Text] [Related]
13. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
[TBL] [Abstract][Full Text] [Related]
14. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans.
Muzi M; Mankoff DA; Link JM; Shoner S; Collier AC; Sasongko L; Unadkat JD
J Nucl Med; 2009 Aug; 50(8):1267-75. PubMed ID: 19617341
[TBL] [Abstract][Full Text] [Related]
15. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
[TBL] [Abstract][Full Text] [Related]
16. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET.
Bart J; Willemsen AT; Groen HJ; van der Graaf WT; Wegman TD; Vaalburg W; de Vries EG; Hendrikse NH
Neuroimage; 2003 Nov; 20(3):1775-82. PubMed ID: 14642487
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of dopamine D3 receptor antagonist 11C-GR218231 as PET tracer for P-glycoprotein.
de Vries EF; Kortekaas R; van Waarde A; Dijkstra D; Elsinga PH; Vaalburg W
J Nucl Med; 2005 Aug; 46(8):1384-92. PubMed ID: 16085598
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil.
Verbeek J; Syvänen S; Schuit RC; Eriksson J; de Lange EC; Windhorst AD; Luurtsema G; Lammertsma AA
Nucl Med Biol; 2012 May; 39(4):530-9. PubMed ID: 22226023
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats.
Luurtsema G; Schuit RC; Klok RP; Verbeek J; Leysen JE; Lammertsma AA; Windhorst AD
Nucl Med Biol; 2009 Aug; 36(6):643-9. PubMed ID: 19647170
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil Analogs To Investigate the Function of P-Glycoprotein in the Blood-Brain Barrier.
Raaphorst RM; Luurtsema G; Schuit RC; Kooijman EJM; Elsinga PH; Lammertsma AA; Windhorst AD
ACS Chem Neurosci; 2017 Sep; 8(9):1925-1936. PubMed ID: 28650628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
